ND L02 s0201

Drug Profile

ND L02 s0201

Alternative Names: ND-L02-s0201

Latest Information Update: 15 Nov 2016

Price : $50

At a glance

  • Originator Nitto Denko
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Hepatic fibrosis
  • No development reported Fibrosis

Most Recent Events

  • 10 Nov 2016 ND L02 s0201 licensed to Bristol-Myers Squibb worldwide which is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Fibrosis(In volunteers) in USA (IV, Injection)
  • 01 Oct 2015 ND L02 s0201 receives Fast Track designation for Hepatic fibrosis, associated with non-alcoholic steatohepatitis and hepatitis C, in USA [IV,Injection]
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top